The short answer
Vilsbøll and colleagues evaluated diabetic retinopathy data from across the SUSTAIN clinical trial programme, published in Diabetes, Obesity and Metabolism in 2018 under a title linking the reduction in glycated haemoglobin to retinopathy risk.
Key facts
- Analysis
- Vilsbøll 2018 (PMID 29178519)
- Journal
- Diabetes Obes Metab, April 2018
- Source data
- SUSTAIN clinical trial programme
- Title frames risk via
- Reduction in glycated haemoglobin
- Later review
- Marchand 2021, Diabet Med (PMID 32799379)
- Recent overview
- Vujosevic 2025 (PMID 40586870)
Why a retinopathy signal was examined at all
Diabetic retinopathy is among the most consequential microvascular complications of diabetes, so any signal in a large trial programme of a diabetes medicine warrants dedicated analysis. Pooling across a programme rather than reporting one trial gives enough events to describe the pattern rather than count a handful.
What the paper's title is doing
It reads semaglutide, reduction in glycated haemoglobin, and the risk of diabetic retinopathy. That places the HbA1c reduction between the compound and the outcome, framing the question as whether the risk follows from the glycaemic improvement rather than from the drug acting on the eye. Titles are chosen carefully, and this one states a hypothesis.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
Why that framing is biologically motivated
Rapid improvement in glycaemic control has long been associated with transient worsening of retinopathy, observed across intensive-control studies well before any incretin existed. A compound that lowers HbA1c substantially and quickly would be expected to encounter that phenomenon, and encountering it would say nothing specific about the compound.
Why the distinction matters clinically
If the association follows from the speed and magnitude of glycaemic improvement, then it is a known property of treating hyperglycaemia effectively rather than a property of one drug. It is managed by awareness and monitoring in those at risk, and it does not transfer as an argument against the class.
What the later literature added
Marchand and colleagues reviewed GLP-1 receptor agonists and long-term complications with a focus on retinopathy in Diabetic Medicine in 2021. Vujosevic and colleagues published on new generation glycaemic agents and retinopathy progression in Acta Diabetologica in 2025, under a title ending in a question mark. An accurate signal that the question remains live.
What this concerns
Licensed medicines studied in registered trials in people with diabetes under clinical supervision. Nothing supplied on this site is semaglutide, affects glycaemic control, or has any bearing on eye health in any person.
Frequently asked questions
Did the SUSTAIN programme show a retinopathy signal?
It produced retinopathy data warranting a dedicated pooled analysis, published by Vilsbøll and colleagues in 2018.
Why does the title mention HbA1c reduction?
It places the glycaemic improvement between the drug and the outcome, framing the question as whether risk follows from that improvement rather than from the drug itself.
Is the question settled?
No. Vujosevic's 2025 overview title ends in a question mark, which accurately reflects that it remains live.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedVilsbøll T et al., Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. Diabetes Obes Metab 2018 (PMID 29178519)pubmed.ncbi.nlm.nih.gov
- PubMedMarchand L et al., GLP-1 receptor agonists in type 2 diabetes and long-term complications: focus on retinopathy. Diabet Med 2021 (PMID 32799379)pubmed.ncbi.nlm.nih.gov
- PubMedVujosevic S et al., New generation agents for glycemic control and diabetic retinopathy progression: what we need to know? Acta Diabetol 2025 (PMID 40586870)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- Why Fixing Glucose Quickly Can Make the Eye Worse FirstRapid improvement in glycaemic control is associated with transient worsening of retinopathy. It predates every modern diabetes drug.
- A Third Way an Adverse Effect Can AriseSome effects follow not from the drug but from what the drug achieves. Any intervention producing the same change as fast would produce them too.
- Comparing Things That Were Never ComparedWhen no head-to-head exists, a network meta-analysis links treatments through shared comparators. It rests on an assumption worth understanding.
- A Second Entrant to Tirzepatide's MechanismVK2735 is a GIP/GLP-1 dual agonist - the same receptor pair as tirzepatide. Its Phase 2 VENTURE study ran 13 weeks, too short to compare with 72-week data.
- A GLP-1/Glucagon Dual Aimed at the LiverPemvidutide pairs GLP-1 with glucagon receptor agonism and was studied for 24 weeks in metabolic dysfunction-associated steatotic liver disease.